Pharmacological management update: Clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients

Terence Rong De Ng; Eduardo Bruera; Sriram Yennurajalingam

doi:10.21037/tcr.2016.09.10

Pharmacological management update: Clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients

Terence Rong De Ng, Eduardo Bruera, Sriram Yennurajalingam

Palliative, Rehabilitation, and Integrative Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer cachexia is a debilitating and multifactorial metabolic condition that is highly prevalent among advanced cancer patients. Currently there are limited effective pharmacological treatment options for the management of cancer cachexia. In recent years, there is an increasing attention on the use of ghrelinreceptor agonists in the treatment of cancer cachexia. In this perspective, we discuss recent clinical trials that have evaluated the efficacy and safety of ghrelin-receptor agonist, anamorelin for the treatment of anorexia cancer cachexia syndrome and its potential role of anamorelin in clinical care in advanced cancer patients.

Original language	English (US)
Pages (from-to)	S491-S496
Journal	Translational Cancer Research
Volume	5
DOIs	https://doi.org/10.21037/tcr.2016.09.10
State	Published - 2016

Keywords

Anamorelin
Anorexia
Cancer cachexia
Cancer related fatigue
Ghrelin receptor agonists

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.21037/tcr.2016.09.10

Cite this

@article{2c2102f2b75c429a84916ff00f717890,

title = "Pharmacological management update: Clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients",

abstract = "Cancer cachexia is a debilitating and multifactorial metabolic condition that is highly prevalent among advanced cancer patients. Currently there are limited effective pharmacological treatment options for the management of cancer cachexia. In recent years, there is an increasing attention on the use of ghrelinreceptor agonists in the treatment of cancer cachexia. In this perspective, we discuss recent clinical trials that have evaluated the efficacy and safety of ghrelin-receptor agonist, anamorelin for the treatment of anorexia cancer cachexia syndrome and its potential role of anamorelin in clinical care in advanced cancer patients.",

keywords = "Anamorelin, Anorexia, Cancer cachexia, Cancer related fatigue, Ghrelin receptor agonists",

author = "{De Ng}, {Terence Rong} and Eduardo Bruera and Sriram Yennurajalingam",

year = "2016",

doi = "10.21037/tcr.2016.09.10",

language = "English (US)",

volume = "5",

pages = "S491--S496",

journal = "Translational Cancer Research",

issn = "2218-676X",

publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Pharmacological management update

T2 - Clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients

AU - De Ng, Terence Rong

AU - Bruera, Eduardo

AU - Yennurajalingam, Sriram

PY - 2016

Y1 - 2016

N2 - Cancer cachexia is a debilitating and multifactorial metabolic condition that is highly prevalent among advanced cancer patients. Currently there are limited effective pharmacological treatment options for the management of cancer cachexia. In recent years, there is an increasing attention on the use of ghrelinreceptor agonists in the treatment of cancer cachexia. In this perspective, we discuss recent clinical trials that have evaluated the efficacy and safety of ghrelin-receptor agonist, anamorelin for the treatment of anorexia cancer cachexia syndrome and its potential role of anamorelin in clinical care in advanced cancer patients.

AB - Cancer cachexia is a debilitating and multifactorial metabolic condition that is highly prevalent among advanced cancer patients. Currently there are limited effective pharmacological treatment options for the management of cancer cachexia. In recent years, there is an increasing attention on the use of ghrelinreceptor agonists in the treatment of cancer cachexia. In this perspective, we discuss recent clinical trials that have evaluated the efficacy and safety of ghrelin-receptor agonist, anamorelin for the treatment of anorexia cancer cachexia syndrome and its potential role of anamorelin in clinical care in advanced cancer patients.

KW - Anamorelin

KW - Anorexia

KW - Cancer cachexia

KW - Cancer related fatigue

KW - Ghrelin receptor agonists

UR - http://www.scopus.com/inward/record.url?scp=84992077677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992077677&partnerID=8YFLogxK

U2 - 10.21037/tcr.2016.09.10

DO - 10.21037/tcr.2016.09.10

M3 - Article

AN - SCOPUS:84992077677

SN - 2218-676X

VL - 5

SP - S491-S496

JO - Translational Cancer Research

JF - Translational Cancer Research

ER -

Pharmacological management update: Clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this